Here’s What Wall Street Thinks About Humana Inc (HUM)

​Humana Inc. (NYSE:HUM) is one of the Best 52-Week Low Stocks to Invest In. Wall Street is bullish on Humana Inc. (NYSE:HUM) ahead of its fiscal Q4 2025 earnings, expected to be released on February 11, 2026. The Street expects the company to post quarterly revenue around $32.08 billion, along with a negative GAAP EPS of $4.08.

​Recently, on January 27, David S Macdonald from Truist Financial reiterated a Hold rating on the stock without disclosing any price targets. On the same day, Lance Wilkes from Bernstein reiterated a Buy rating on Humana Inc. (NYSE:HUM) with a $344 price target.

​On January 27, Piper Sandler released a research note discussing the impact of Medicare Advantage Advance Notice on healthcare stocks. Medicare Advantage is a private insurance alternative to traditional Medicare, which covers roughly half of the US seniors. The latest notice sets a benchmark for insurers such as Humana Inc, which is expected to directly impact revenue and profit margins.

​Moreover, on the same day, Reuters reported that the Trump administration has proposed a much smaller than expected increase in 2027 Medicare Advantage rates. Since the news, the share price of Humana Inc. (NYSE:HUM) has fallen more than 24%, bringing it close to its 52-week lows.

​Humana Inc. (NYSE:HUM) is a leading health insurance and well-being company focused on Medicare Advantage plans, Medicaid services, and specialty insurance products for individuals and employer groups.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.